

Recommendations of the [Norfolk & Waveney Therapeutics Advisory Group \(TAG\)](#) and the Norfolk & Waveney CCGs' Drugs & Therapeutics Committee (D&TC) - January 2019

Recommending Body	Drug / Product	Indication for Use	TAG Clinical Recommendation	N&W CCGs' D&TC Commissioning Recommendation to the CCGs	
Regional Medicines Optimisation Committees (RMOCs):					
<p>South RMOC: Guidance - Prescribing of Liothyronine (v2 November 2018)</p>	For noting and comparing against the previously classified indications for use with reference EoE PAC Guidance Statement (agreed May 2018):		<p>The TAG considered the guidance from RMOC and reviewed the previously agreed traffic light classifications as recorded in the table in the previous column ← The TAG also considered a document received by the D&TC in December 2018 from the Norfolk Thyroid Support Group (TSG), which listed concerns regarding the RMOC guidance on Liothyronine. The TAG noted the TSG's request that their document be considered but was unable to make any recommendations in the absence of clinical evidence to support the TSG's position submitted by a local specialist clinician, or any revised guidance from NHS England.</p>	<p>The D&TC noted and supported the TAG's:</p> <ul style="list-style-type: none"> revised recommendations for previously considered clinical indications, and also the additional clinical indication and products which were not recommended for use. 	
	Indications for liothyronine agreed in Norfolk and Waveney	Traffic Light currently in place			Traffic light recommended January 2019
	ROUTINE use for long term for treatment of Hypothyroidism	Double Red			Double Red
	RESTRICTED use for long term treatment in rare cases of levothyroxine-induced liver injury	Red			Green – for new patients, NHS Consultant to prescribe for 3 months then GP. For existing patients, NHS consultant to review, then, if appropriate, to the GP.
	RESTRICTED use for patients on levothyroxine for hypothyroidism who continue to suffer with symptoms despite adequate biochemical correction	Red			Green – for new patients, NHS Consultant to prescribe for 3 months then GP. For existing patients, NHS Consultant to review, then, if appropriate, to the GP.
	Niche, short-term use for up to three months in patients awaiting surgery pre-cancer therapy	Red			Red
	Patients with thyroid cancer following thyroid surgery, pre- and post- radio iodine ablation	Red			Red

Recommending Body	Drug / Product	Indication for Use		TAG Clinical Recommendation	<i>N&W CCGs' D&TC Commissioning Recommendation to the CCGs</i>
	Armour thyroid and other unlicensed thyroid extract products, plus compounded thyroid hormones, iodine containing preparations, dietary supplementation: Not commissioned for any indication	Double Red	Additional text from RMOC guidance also supported by the TAG. Double Red		
	Resistant depression	Not previously listed – added from RMOC guidance	Double Red pending an evidence-based business and costed application for use.		